Alzheimer's disease (AD) is characterized by the deposition of amyloid β peptide (Aβ) in the
brain. The neuropeptide somatostatin (SST) regulates Aβ catabolism by enhancing …

Alzheimer's disease is the most common neurodegenerative disorder characterized by the
pathological aggregation of amyloid-β (Aβ) peptide. A potential therapeutic intervention in …

The neuroendocrine peptide somatostatin (SST) has long been thought of as influencing the
deposition of the amyloid β peptide (Aβ) in Alzheimer's disease (AD). Missing have been in …

The brain noradrenergic system is critical for normal cognition and is affected at early stages
in Alzheimer's disease (AD). Here, we reveal a previously unappreciated direct role of …

Serotoninergic activation which decreases brain Aβ peptides is considered beneficial in
mouse models for Alzheimer's disease (AD), but the mechanisms involved remain unclear …

Background: Aggregation of the amyloid-beta (Aβ) peptide is one of the main
neuropathological events in Alzheimer's disease (AD). Neprilysin is the major enzyme …

Amyloid-beta (Aβ) peptide accumulation in the brain is a pathological hallmark of all forms of
Alzheimer's disease. An imbalance between Aβ production and clearance from the brain …

Among the central features of Alzheimer's disease (AD) progression are altered levels of the
neuropeptide somatostatin (SST), and the colocalisation of SST-positive interneurons (SST …

Background Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key
pathological events in Alzheimer's disease (AD). Reducing Aβ levels in the brain by …

Alzheimer's disease (AD) is characterized by an accumulation of Amyloid-β (Aβ), released
by sequential proteolytic processing of the amyloid precursor protein (APP) by β-and γ …